Lei Zhang

Dr. Lei Zhang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
ZZZhi‐Guo Zhou
Zhi‐Guo Zhou
DYDong‐Sheng Yue
Dong‐Sheng Yue
CMChen‐Lu Mu
Chen‐Lu Mu
LZLei Zhang
Lei Zhang
Ma's research shows N95 masks, medical masks, even homemade masks could block at least 90% of the virus in aerosols1. This study puts the debate on whether the public wear masks back on the table. Recently Science interviewed Dr. Gao, director‐general of Chinese Center for Disease Control and Prevention (CDC).

4 March 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
ZZZhi-Guo Zhou
Zhi-Guo Zhou
SXShu-Min Xie
Shu-Min Xie
JZJing Zhang
Jing Zhang
FZFang Zheng
Fang Zheng
DJDi-Xuan Jiang
Di-Xuan Jiang
LZLei Zhang
Lei Zhang
Background: The coronavirus disease-19 (COVID-19) has spread globally with more than 80,000 people infected, and nearly 3000 patients died. Currently, we are in an urgent need for effective treatment strategy to control the clinical deterioration of COVID-19 patients. Methods: The clinical data of 10 COVID-19 patients receiving short-term moderate-dose corticosteroid (160mg/d) plus immunoglobulin (20g/d) were studied in the North Yard of The First Hospital of Changsha, Hunan from January 17th to February 27th, 2020. Epidemiological, clinical, laboratory, radiological findings were analyzed. Results: After treatment with combination of low-dose corticosteroid (40-80mg/d) and immunoglobulin (10g/d), patients’ lymphocyte count (0.88±0.34 vs 0.59±0.18, P<0.05), oxygenation index including SPO2 (94.90±2.51 vs 90.50±5.91, P<0.05) and PaO2/FiO2 (321.36±136.91 vs 129.30±64.97, P<0.05) were significantly lower than pre-treatment, and CT showed that the pulmonary lesion deteriorated in all patients. While after treatment of short-term moderate-dose corticosteroid plus immunoglobulin, patients’ APACHE Ⅱ score (9.10±6.15 vs 5.50±9.01, P<0.05), body temperature (37.59±1.16 vs 36.46±0.25, P<0.05), lymphocyte count (0.59±0.18 vs 1.36±0.51, P<0.05), Lactate dehydrogenase (419.24±251.31 vs 257.40±177.88, P<0.05), and C-reactive protein (49.94±26.21 vs 14.58±15.25, P<0.05) significantly improved compared with post-treatment with low-dose therapy. In addition, oxygenation index including SPO2 (90.50±5.91 vs 97.50±1.18, P<0.05), PaO2 (60.47±14.53 vs 99.07±34.31, P<0.05), and PaO2/FiO2 (129.30±64.97 vs 340.86±146.72, P<0.05) significant improved. Furthermore, CT showed that pulmonary lesions obviously improved in 7 patients. After systematic therapy, 4 out of 10 COVID-19 patients recovered and discharged. Conclusions: Short-term moderate-dose corticosteroid plus immunoglobulin is effective for reversing the continued deterioration of COVID-19 patients who failed to respond to the low-dose therapy. Funding: This work was supported by the Innovative Major Emergency Project Funding against the New Coronavirus Pneumonia in Hunan Province (Dr. Ji-Yang Liu, number 2020SK3014; Dr. Yuan-Lin Xie, number 2020SK3013).

20 February 2018 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
KZK. Zhang
K. Zhang
JTJ. Tian
J. Tian
ZHZ. He
Z. He
WSW. Sun
W. Sun
BPB. Pekbay
B. Pekbay
LZLei Zhang
Lei Zhang

24 November 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZZZhi-Guo Zhou
Zhi-Guo Zhou
DJDi-Xuan Jiang
Di-Xuan Jiang
SXShu-Min Xie
Shu-Min Xie
JZJing Zhang
Jing Zhang
FZFang Zheng
Fang Zheng
LZLei Zhang
Lei Zhang

1 April 2017 in The Breast
Verified
Journal Article
Closed access
ZZZhen Zhang
Zhen Zhang
XZXian Zhang
Xian Zhang
LWLing Wei
Ling Wei
YLYunshou Lin
Yunshou Lin
DWDongwen Wu
Dongwen Wu
LZLei Zhang
Lei Zhang

12 June 2020 in Research Square
Verified
Preprint
Open access
PDF file
ZZZhi-Guo Zhou
Zhi-Guo Zhou
SXShu-Min Xie
Shu-Min Xie
JZJing Zhang
Jing Zhang
FZFang Zheng
Fang Zheng
JLJi-Heng Liu
Ji-Heng Liu
LZLei Zhang
Lei Zhang
Background: The coronavirus disease-19 (COVID-19) has spread globally with more than 6,750,000 people infected, and nearly 400,000 patients died. Currently, we are in an urgent need for effective treatment strategy to control the clinical deterioration of COVID-19 patients.Methods: The clinical data of 10 COVID-19 patients receiving short-term moderate-dose corticosteroid (160mg/d) plus immunoglobulin (20g/d) were studied in the North Yard of The First Hospital of Changsha, Hunan from January 17th to February 27th, 2020. Epidemiological, clinical, laboratory, radiological findings were analyzed. Results: After treatment with combination of low-dose corticosteroid (40-80mg/d) and immunoglobulin (10g/d), patients’ lymphocyte count (0.88±0.34 vs 0.59±0.18, P<0.05), oxygenation index including SPO2 (94.90±2.51 vs 90.50±5.91, P<0.05) and PaO2/FiO2 (321.36±136.91 vs 129.30±64.97, P<0.05) were significantly lower than pre-treatment, and CT showed that the pulmonary lesion deteriorated in all patients. While after treatment of short-term moderate-dose corticosteroid plus immunoglobulin, patients’ APACHE Ⅱ score (9.10±6.15 vs 5.50±9.01, P<0.05), body temperature (37.59±1.16 vs 36.46±0.25, P<0.05), lymphocyte count (0.59±0.18 vs 1.36±0.51, P<0.05), Lactate dehydrogenase (419.24±251.31 vs 257.40±177.88, P<0.05), and C-reactive protein (49.94±26.21 vs 14.58±15.25, P<0.05) significantly improved compared with post-treatment with low-dose therapy. In addition, oxygenation index including SPO2 (90.50±5.91 vs 97.50±1.18, P<0.05), PaO2 (60.47±14.53 vs 99.07±34.31, P<0.05), and PaO2/FiO2 (129.30±64.97 vs 340.86±146.72, P<0.05) significant improved. Furthermore, CT showed that pulmonary lesions obviously improved in 7 patients. After systematic therapy, 4 out of 10 COVID-19 patients recovered and discharged.Conclusions: Short-term moderate-dose corticosteroid plus immunoglobulin is effective for reversing the continued deterioration of COVID-19 patients who failed to respond to the low-dose therapy.